Biorestorative Therapies Inc (BRTX) Stock Price, Quote & News

Company Profile

BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. It develops programs relate to the treatment of disc/spine disease and metabolic disorders. The company's products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, as well as used for the non-surgical treatment of painful lumbosacral di...

Industry: Biotechnology

Sector: Healthcare

Phone: 631 760 8100

Website: www.biorestorative.com

Address:

40 Marcus Drive, Suite 1, Melville, United States

Greatguns Jun. 23 at 6:49 PM

$BRTX LSEG maintains a current price target of $13 for BRTX

0 · Reply

GDog877 Jun. 23 at 1:40 PM

$BRTX Did you know the capital loss deduction limit has been stuck at $3,000 since 1978? That’s nearly 50 years with zero adjustment for inflation. Imagine still being limited to a $3K deduction 30 years from now—while everything else keeps getting more expensive. That’s why I support the Capital Loss Inflation Fairness Act (H.R. 2684), which would raise the limit and adjust it for inflation going forward. Most retail investors will take losses at some point. This bill is a common-sense update that reflects today’s economic reality. 👉 You can learn more about the bill here: https://norman.house.gov/news/documentsingle.aspx?DocumentID=1611 📞 Find your representative and ask them to support it: www.house.gov/representatives/find-your-representative

0 · Reply

Black_Jobs Jun. 20 at 4:16 PM

$BRTX do not buy this stock.. stay away.. this company does nothing but dilute. they don't care about share holders.

0 · Reply

MrTicker Jun. 18 at 1:38 PM

$BRTX BioRestorative to Participate in Benzinga All-Access Show Today to Discuss Compelling BRTX-100 Clinical Data, Leadership Enhancements and Strategic updates GLOBENEWSWIRE 8:35 AM ET 6/18/2025

0 · Reply

Rahmmy Jun. 17 at 8:20 PM

$BRTX As of 3/31 they had 9 million in liquidity and they burn about $1 million per month. So let’s say they’ve now got $6.5 million…or 6.5 months till they run out of cash and have to shut down. You think they’ll burn $2 million of that for a buyback? I don’t. Total Hail Mary attempt to manipulate the stock. IMO this should be illegal…if it isn’t already.

2 · Reply

Teeemo16 Jun. 17 at 6:01 PM

$BRTX They wouldn’t be preparing for a buyback if they also didn’t see some near term possibilities of real revenue generation

0 · Reply

MrTicker Jun. 17 at 5:38 PM

$BRTX low volume uptrend on solid share buy back news.. Should pick up more in the afternoon.

0 · Reply

chrsc Jun. 17 at 1:49 PM

$BRTX just added another tranche of shares at $1.65 adding 15% to my postion

1 · Reply

InsaneTang Jun. 17 at 1:46 PM

$BRTX Just announced a $2M share buyback major confidence signal + FDA fast-tracked BRTX‑100 Phase 2 data shows continued strength in pain & function outcomes. With the float tight at ~5M shares, any share withdrawal boosts upside. Clinical pipeline + capital return = bullish setup. #Biotech #BRTX #StemCellTherapy

0 · Reply

chrsc Jun. 17 at 1:35 PM

$BRTX interesting way to use capital, and put a floor in the stock price. I like the idea. didn't have a stock buyback on my radar, but price is going to go up.

0 · Reply

BioRestorative to Participate in Benzinga All-Access Show Today to Discuss Compelling BRTX-100 Clinical Data, Leadership Enhancements and Strategic updates

Jun 17, 2025, 9:25 AM EDT - 13 days ago

BioRestorative Announces Share Repurchase Program

Jun 13, 2025, 7:45 AM EDT - 17 days ago

BioRestorative Reports Compelling Preliminary Data for FDA-Fast-Tracked BRTX-100 – an Autologous Stem Cell Therapy to Treat Chronic Lumbar Disc Disease

Jun 9, 2025, 7:45 AM EDT - 21 days ago

BioRestorative to Present Major Update on Promising Preliminary Phase 2 BRTX-100 Data at ISSCR 2025

May 14, 2025, 8:46 PM EDT - 6 weeks ago

BioRestorative Therapies, Inc. (BRTX) Q1 2025 Earnings Call Transcript

May 13, 2025, 9:15 AM EDT - 6 weeks ago

Phase 2 Trial of BRTX-100 in cLDD Continues to Generate Positive Preliminary Blinded Data

May 8, 2025, 4:30 PM EDT - 7 weeks ago

BioRestorative Therapies to Report First Quarter 2025 Financial Results and Host Conference Call on May 14, 2025

May 7, 2025, 9:15 AM EDT - 7 weeks ago

BioRestorative to Present a BRTX-100 Clinical Update at ISCT 2025

Apr 15, 2025, 8:30 AM EDT - 2 months ago

BioRestorative to Participate in Benzinga All-Access Show Today to Discuss Recent Achievements of Key Clinical & Regulatory Milestones, and Highlight Commercial Opportunities

Apr 10, 2025, 9:15 AM EDT - 2 months ago

BioRestorative Confirms No Material Impact from Reciprocal Tariffs; All BRTX-100 Production & Manufacturing Performed in the United States

Mar 27, 2025, 8:10 PM EDT - 3 months ago

BioRestorative Therapies, Inc. (BRTX) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 9:45 AM EST - 4 months ago

BioRestorative Announces FDA Clearance of IND for Phase 2 Trial of BRTX-100 in Chronic Cervical Discogenic Pain

Feb 26, 2025, 8:15 PM EST - 4 months ago

BioRestorative Announces Updated Time for February 27th Webcasted Conference Call to Discuss Clinical Pipeline Update

Feb 20, 2025, 8:30 AM EST - 4 months ago

BioRestorative Receives FDA Fast Track Designation for BRTX-100 Chronic Lumbar Disc Disease Program

Dec 5, 2024, 6:45 AM EST - 7 months ago

BioRestorative Therapies Announces Notice of Allowance of Key New Patent Protecting ThermoStem® Metabolic Disease Program

Nov 13, 2024, 7:53 PM EST - 8 months ago

BioRestorative Therapies, Inc. (BRTX) Q3 2024 Earnings Call Transcript

Nov 5, 2024, 7:10 AM EST - 8 months ago

BioRestorative Therapies Receives Expanded Tissue License from New York State Department of Health

Oct 3, 2024, 4:15 PM EDT - 9 months ago

BioRestorative Therapies to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Sep 19, 2024, 6:55 AM EDT - 10 months ago

BioRestorative Therapies' IFATS 2024 Presentation to Feature ThermoStem® Platform's Potential to Deliver a Superior Efficacy and Tolerability Profile Over GLP-1 Drugs

Aug 13, 2024, 11:26 PM EDT - 11 months ago

BioRestorative Therapies, Inc. (BRTX) Q2 2024 Earnings Call Transcript

Jul 23, 2024, 7:10 AM EDT - 1 year ago

BioRestorative Therapies' Chief Scientist Named New Section Editor of the Prestigious Journal of Translational Medicine

Jun 27, 2024, 7:40 AM EDT - 1 year ago

BioRestorative Therapies Announces Notice of Allowance for Patent Covering Fundamental Aspect of ThermoStem® Metabolic Disease Program

Jun 17, 2024, 7:05 AM EDT - 1 year ago

BioRestorative Therapies Regains Compliance with Nasdaq Listing Rule 5250(c)(1); Reports First Quarter 2024 Financial Results

Jun 13, 2024, 7:00 AM EDT - 1 year ago

BioRestorative Therapies in Substantive Discussions for Potential License Agreement for ThermoStem® Metabolic Disease Program

Jun 4, 2024, 8:50 AM EDT - 1 year ago

BioRestorative Therapies, Inc. to attend the Jefferies 2024 Healthcare Conference

May 24, 2024, 7:45 PM EDT - 1 year ago

BioRestorative Therapies Announces Receipt of Nasdaq Non-Compliance Notice

May 15, 2024, 9:00 AM EDT - 1 year ago

BioRestorative Therapies (NASDAQ:BRTX) Announces Commercial Agreement With Cartessa, Further Expanding Into $75.46 Billion Aesthetics Market

May 14, 2024, 7:08 PM EDT - 1 year ago

BioRestorative Therapies, Inc. (BRTX) Q1 2024 Earnings Call Transcript

May 14, 2024, 4:10 PM EDT - 1 year ago

BioRestorative Therapies Provides First Quarter 2024 Business Update

May 8, 2024, 7:30 AM EDT - 1 year ago

BioRestorative Therapies Enhances Preclinical Metabolic Program with a Novel Exosome-Based Biologic Targeting Obesity

Apr 30, 2024, 4:15 PM EDT - 1 year ago

BioRestorative Therapies to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

Apr 30, 2024, 7:30 AM EDT - 1 year ago

BioRestorative Therapies Announces Transformative Commercial Agreement with Cartessa, a Global Leader in Medical Aesthetics Technology

Apr 16, 2024, 7:45 AM EDT - 1 year ago

BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment

Apr 8, 2024, 7:45 AM EDT - 1 year ago

BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease

Apr 3, 2024, 4:38 PM EDT - 1 year ago

BioRestorative Therapies Announces Filing of Form S-1 Registration Statement to Register for Resale Common Stock Underlying Previously Issued Warrants

Apr 1, 2024, 7:45 AM EDT - 1 year ago

BioRestorative Therapies Announces Filing of 2023 Annual Report on Form 10-K

Mar 11, 2024, 4:15 PM EDT - 1 year ago

BioRestorative Therapies to Participate in the 36th Annual ROTH Conference

Feb 14, 2024, 9:15 AM EST - 1 year ago

BioRestorative Therapies Presents Promising Data at Orthopaedic Research Society (ORS) 2024 Annual Meeting

Feb 6, 2024, 8:05 AM EST - 1 year ago

BioRestorative Therapies Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $8.1 Million Gross Proceeds Priced At-the-Market

Feb 5, 2024, 7:30 AM EST - 1 year ago

BioRestorative Therapies Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease

Feb 1, 2024, 7:30 AM EST - 1 year ago

BioRestorative Therapies to Present Preliminary BRTX-100 Clinical Data at the Orthopaedic Research Society (ORS) 2024 Annual Meeting

Dec 12, 2023, 9:15 AM EST - 1 year ago

BioRestorative Therapies Receives a Notice of Allowance by the United States Patent and Trademark Office for a Patent Application Related to its Obesity Program

Oct 9, 2023, 12:10 PM EDT - 1 year ago

BioRestorative Therapies, Inc. to Participate at the ROTH MKM Healthcare Opportunities Conference October 12, 2023 in New York City

Sep 18, 2023, 9:00 AM EDT - 1 year ago

Roth MKM Analyst Projects An Impressive Price Target of $15 Over The Next 12 Months For BioRestorative Therapies (NASDAQ: BRTX), Says “Low Valuation Undeserved”

Sep 12, 2023, 9:00 AM EDT - 1 year ago

BioRestorative Therapies Enters into Supply Agreement with Evolutionary Biologics

Sep 8, 2023, 8:30 AM EDT - 1 year ago

BioRestorative Therapies Announces Activation of Northwell Health in the Company's Phase 2 Clinical Trial Targeting Chronic Lumbar Disc Disease

Aug 30, 2023, 9:00 AM EDT - 1 year ago

As America Grapples With A Deadly Opioid Epidemic, BioRestorative Therapies Is Looking To Treat Chronic Pain Without The Need For Class-A Drugs

Aug 2, 2023, 9:00 AM EDT - 2 years ago

BioRestorative Therapies Gains Additional Investor Confidence As Insider Dale Broadrick, CEO Lance Alstodt Purchase Thousands of Shares

Jul 31, 2023, 8:05 AM EDT - 2 years ago

Chronic Pain Specialist Speaks At Panel On Stem Cell-Based Therapies And The Need For Spinal Care Reform - Insights From The Discussion

Greatguns Jun. 23 at 6:49 PM

$BRTX LSEG maintains a current price target of $13 for BRTX

0 · Reply

GDog877 Jun. 23 at 1:40 PM

0 · Reply

Black_Jobs Jun. 20 at 4:16 PM

$BRTX do not buy this stock.. stay away.. this company does nothing but dilute. they don't care about share holders.

0 · Reply

MrTicker Jun. 18 at 1:38 PM

$BRTX BioRestorative to Participate in Benzinga All-Access Show Today to Discuss Compelling BRTX-100 Clinical Data, Leadership Enhancements and Strategic updates GLOBENEWSWIRE 8:35 AM ET 6/18/2025

0 · Reply

Rahmmy Jun. 17 at 8:20 PM

2 · Reply

Teeemo16 Jun. 17 at 6:01 PM

$BRTX They wouldn’t be preparing for a buyback if they also didn’t see some near term possibilities of real revenue generation

0 · Reply

MrTicker Jun. 17 at 5:38 PM

$BRTX low volume uptrend on solid share buy back news.. Should pick up more in the afternoon.

0 · Reply

chrsc Jun. 17 at 1:49 PM

$BRTX just added another tranche of shares at $1.65 adding 15% to my postion

1 · Reply

InsaneTang Jun. 17 at 1:46 PM

0 · Reply

chrsc Jun. 17 at 1:35 PM

$BRTX interesting way to use capital, and put a floor in the stock price. I like the idea. didn't have a stock buyback on my radar, but price is going to go up.

0 · Reply

TradesWolf Jun. 17 at 1:28 PM

$BRTX share repurchase news

0 · Reply

MrTicker Jun. 17 at 1:27 PM

$BRTX MELVILLE, N.Y., June 17, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc.(BRTX) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, today announced that its Board of Directors has authorized a stock repurchase program under which the Company may repurchase up to $2 million of its outstanding common stock through June 16, 2026

0 · Reply

premarketmaker Jun. 17 at 1:26 PM

$BRTX repurchase plan $2.09+/squeeze

0 · Reply

MrTicker Jun. 17 at 1:26 PM

$BRTX BioRestorative Announces Share Repurchase Program GLOBENEWSWIRE 8:25 AM ET 6/17/2025

0 · Reply

GDog877 Jun. 17 at 11:58 AM

$BRTX Did you know the capital loss deduction limit has been stuck at $3,000 since 1978?????? That’s nearly 50 years with zero adjustment for inflation. Imagine still being limited to a $3K deduction 30 years from now—while everything else keeps getting more expensive. That’s why I support the Capital Loss Inflation Fairness Act (H.R. 2684), which would raise the limit and adjust it for inflation going forward. Most retail investors will take losses at some point. This bill is a common-sense update that reflects today’s economic reality. 👉 You can learn more about the bill here: https://norman.house.gov/news/documentsingle.aspx?DocumentID=1611 📞 Find your representative and ask them to support it: www.house.gov/representatives/find-your-representative

0 · Reply

Mr_Sal Jun. 16 at 8:24 PM

$BRTX https://www.tipranks.com/news/ratings/promising-outlook-for-biorestorative-therapies-buy-rating-supported-by-positive-brtx-100-data-and-fda-fast-track-designation-ratings

0 · Reply

YasirTrades Jun. 16 at 9:54 AM

GLMD might be the most slept-on biotech in the market right now. Trading below cash with a book value north of $20, no debt, and a razor thin float setup is built for a squeeze. The chart is tightening up, momentum indicators are flashing green, and the company has major catalysts ahead tied to its GLP-1 obesity and fibrosis programs. These aren’t fluff angles GLP-1 is one of the hottest biotech spaces with billion-dollar potential. If even a spark of volume or news hits, this has all the ingredients for a 100%+ move. The market hasn’t caught on yet… but when it does, it could be violent. $HTCR, $DRCT, $RIVN, $BRTX

0 · Reply

Coolaa Jun. 16 at 1:15 AM

$BRTX Let’s bounce back this week to $2+

0 · Reply

jParkz Jun. 13 at 10:30 PM

News BioRestorative Reports Compelling Preliminary Data for FDA-Fast-Tracked BRTX-100 - an Autologous Stem Cell Therapy to Treat Chronic Lumbar Disc Disease https://marketwirenews.com/news-releases/biorestorative-reports-compelling-preliminary-data-f-5450466787938712.html $BRTX

0 · Reply

rmbadd Jun. 13 at 7:37 PM

$BRTX glad I passed on this one. good news equals bad stock movement

0 · Reply

prismmarketview Jun. 13 at 6:48 PM

$BRTX https://prismmarketview.com/biorestorative-shares-fall-despite-encouraging-phase-2-data-for-back-pain-stem-cell-therapy/

1 · Reply

PenkeTrading Jun. 13 at 4:21 PM

I found you an Overbought RSI (Relative Strength Index) on the daily chart of BioRestorative Therapies Inc. Is that bullish or bearish? $BRTX #RsiOverbought #NASDAQ

0 · Reply

Market Cap	12.08M
Revenue (ttm)	400,000.00
Net Income (ttm)	-8.98M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,245.00%
Debt to Equity Ratio	0.00

Volume	30,500
Avg Vol	118,408
Day's Range	N/A - N/A
Shares Out	7.51M
Stochastic %K	43%
Beta	76.75
Analysts	Strong Sell
Price Target	$13.00